Overview

palonosetron


Related Overviews

 

'palonosetron' can also refer to...

palonosetron

Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?

O3–003ANTIEMETIC EFFECTS BY 1-DAY VERSUS 3-DAY DEXAMETHASONE WITH PALONOSETRON FOLLOWING PACLITAXEL-CARBOPLATIN THERAPY

O3–004PALONOSETRON IMPROVES DIETARY INTAKE COMPARED TO GRANISETRON IN PATIENTS UNDERGOING HIGHLY EMETOGENIC CHEMOTHERAPY

A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy

A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation

Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial

O2-18-2Risk factors of CINV induced by CDDP in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study

1551PRisk factors of chemotherapy-induced nausea and vomiting during cisplatin regimen in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (phase lll)

1547PDPhase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

415PEvaluation of palonosetron in combination with 1-day dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of paclitaxel and carboplatin for gynecologic malignancies

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

 

More Like This

Show all results sharing this subject:

  • Clinical Pharmacology and Therapeutics

GO

Show Summary Details

Quick Reference

A second generation 5-HT3 antagonist, used to treat chemotherapy-induced nausea and vomiting. TN Aloxi.

Subjects: Clinical Pharmacology and Therapeutics.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.